Results 41 to 50 of about 3,210 (194)

miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling

open access: yesCancer Cell International, 2017
Background Hepatocellular carcinoma (HCC) remains one of the most lethal cancers. MicroRNA-155 (miR-155) and collagen triple helix repeat containing 1 (CTHRC1) were found to be involved in hepatocarcinogenesis, but their detailed functions in HCC are ...
Gang Chen   +8 more
doaj   +1 more source

High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation

open access: yesJournal of Experimental & Clinical Cancer Research, 2017
Background Oesophageal cancer is one of the most common malignancies worldwide,and oesophageal squamous cell carcinoma (ESCC) is the predominant histological type both globally and in China.
Chunni Wang   +7 more
doaj   +1 more source

Pharmacokinetic properties of Cthrc1.

open access: yes, 2013
(A) Clearance curve of 125I-Cthrc1 injected intra-arterially into Cthrc1 null mice. The half-life of the protein was calculated to be 146 min. (B) SDS-PAGE and autoradiographic analysis of plasma 30 min after 125I-Cthrc1 injection. Monomeric, dimeric and
Nicole G. Perreault (303994)   +4 more
core   +1 more source

CTHRC1 activates RhoA activity.

open access: yes, 2013
(A) Pull-down assay of Rho family proteins showed that knockdown of CTHRC1 inhibited the activation of RhoA, but not Rac1 or Cdc42. (B) Treating Huh7 cells with recombinant CTHRC1 (100 ng/ml) activated the RhoA pathway.
Yu-Ling Chen (399126)   +4 more
core   +1 more source

CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes

open access: yesScientific Reports, 2021
According to the previous reports, the collagen triple helix repeat containing 1 (CTHRC1) causes tumorigenesis by modulating the tumor microenvironment, however, the evidence is limited to a few human cancer subtypes.
Nuzhat Sial   +16 more
doaj   +1 more source

CTHRC1 is a Potential Prognostic Biomarker and Correlated with Macrophage Infiltration in Breast Cancer

open access: yesInternational Journal of General Medicine, 2022
Zejun Wang,1,* Shichao Zhang,2,* Chaochao Zheng,3 Kaide Xia,4 Liangquan Sun,4 Xuejie Tang,4 Fulin Zhou,4 Yan Ouyang,2 Fuzhou Tang3 1Department of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang ...
Wang Z   +8 more
doaj  

ABERRANT EXPRESSION OF COL14A1, CELRS3, and CTHRC1 IN BREAST CANCER СELLS

open access: yesExperimental Oncology, 2023
Background: Collagens, which are the major components of the extracellular matrix involved in the regulation of tumor microenvironment, could be differentially expressed in breast cancer (BC) with different transcriptome profiling. Aim: To analyze the transcript level expression of COL1A1, COL5A1, COL10A1, COL11A1, COL12A1, COL14A1, CTHRC1, and CELRS3 ...
Shreshtha, Malvia   +5 more
openaire   +2 more sources

CD248/Endosialin Regulates Synovial Fibroblast State to Control Coupling of Inflammation and Bone Damage in Murine Models of Immune‐Mediated Inflammatory Arthritis and Aging

open access: yesArthritis &Rheumatology, EarlyView.
Objective Synovial fibroblasts directly contribute to inflammation and damage in immune‐mediated inflammatory arthritis. CD248/endosialin is expressed by fibroblasts in the synovium, is highly up‐regulated during inflammation, and has been proposed as a potential therapeutic target.
Samuel Kemble   +12 more
wiley   +1 more source

CTHRC1 promotes tumor migration and invasion.

open access: yes, 2013
(A) shRNA#1 and #5 markedly reduced CTHRC1 mRNA and protein in HA22T cells. (B) Knockdown of CTHRC1 markedly decreased the amount of CTHRC1 in the culture medium. (C) Depletion of CTHRC1 did not affect proliferation, as measured by MTT assay.
Yu-Ling Chen (399126)   +4 more
core   +1 more source

Kit for Detecting CTHRC1 in a Sample [PDF]

open access: yes, 2013
The invention provides methods for the treatment of coronary heart disease, peripheral vascular disease, stroke, and ischemia featuring agents that interfere with the expression or activity of Cthrc1. The invention also provides the use of Cthrc1 peptide
Lindner, Volkhard   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy